ストックスクリーナーアプリを入手
0.2949
1.69%
0.0049
前日終値:
$0.29
開ける：
$0.31
24時間の取引高:
41,152
Relative Volume:
0.04
時価総額：
$10.21M
収益：
-
当期純損益:
$-12.29M
株価収益率:
-0.2836
EPS:
-1.0399
ネットキャッシュフロー:
$-9.07M
1週間 パフォーマンス:
+2.04%
1か月 パフォーマンス:
-13.01%
6か月 パフォーマンス:
-73.43%
1年 パフォーマンス:
-79.08%
1日の値動き範囲:
$0.2851
$0.31
1週間の範囲:
$0.2701
$0.315
52週間の値動き範囲:
$0.2178
$1.73
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
名前
Akari Therapeutics Plc Adr
セクター
電話
(929) 274-7510
住所
401 EAST JACKSON STREET, TAMPA
AKTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
0.2858 | 10.36M | 0 | -12.29M | -9.07M | -1.0399 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.88 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
799.63 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.71 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.19 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.23 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | 開始されました | Ladenburg Thalmann | Buy |
| 2025-07-18 | 開始されました | Maxim Group | Buy |
| 2019-01-04 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | アップグレード | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | 繰り返されました | Chardan Capital Markets | Sell |
| 2016-07-11 | 開始されました | Chardan Capital Markets | Sell |
すべてを表示
Akari Therapeutics Plc Adr (AKTX) 最新ニュース
Akari Therapeutics Plc ADR (AKTX) Stock Sees a-0.57% Decrease - News Heater
Akari Therapeutics advances ADC oncology program with novel payload By Investing.com - Investing.com South Africa
Akari Therapeutics advances ADC oncology program with novel payload - Investing.com India
Operating cash flow per share of Akari Therapeutics Plc Sponsored ADR – FWB:CLA - TradingView — Track All Markets
AKTX SEC FilingsAkari Therapeutics Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Expands By 650.6% - Defense World
Akari begins GMP manufacturing of lead ADC program with WuXi XDC - Investing.com
Akari begins GMP manufacturing of lead ADC program with WuXi XDC By Investing.com - Investing.com South Africa
Akari Therapeutics Releases Virtual Investor “What This Means” Segment - Sahm
Akari Therapeutics (Nasdaq: AKTX) sells 10M ADSs and issues new warrants - Stock Titan
Akari Therapeutics raises $5 million in at-market offering By Investing.com - Investing.com South Africa
Akari Therapeutics raises $5 million in at-market offering - Investing.com India
Akari Therapeutics stock rises on promising pancreatic cancer drug data By Investing.com - Investing.com South Africa
Akari Therapeutics stock rises on promising pancreatic cancer drug data - Investing.com
Views of Wall Street’s Leading Experts on Moderna Inc - setenews.com
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment - Sahm
Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance - Investing.com
Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance By Investing.com - Investing.com South Africa
Akari Therapeutics Announces Release of the Next CEO Corner Segment - Sahm
Tops & Flops Stocks - sharewise.com
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer - Finviz
Akari Therapeutics appoints Kameel Farag as interim CFO By Investing.com - Investing.com South Africa
Akari Therapeutics appoints Kameel Farag as interim CFO - Investing.com
[DEF 14A] Akari Therapeutics Plc Definitive Proxy Statement - Stock Titan
[S-1] Akari Therapeutics Plc Files IPO Registration Statement | AKTX SEC FilingForm S-1 - Stock Titan
Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m - Sahm
Why Akari Therapeutics Plc Depositary Receipt stock appeals to analystsWall Street Watch & Verified Momentum Stock Watchlist - newser.com
[PRE 14A] Akari Therapeutics Plc Preliminary Proxy Statement - Stock Titan
Akari Therapeutics Plc ADR (AKTX) looking to reclaim success with recent performance - setenews.com
Akari Therapeutics forms scientific advisory board with Dr. Hurvitz By Investing.com - Investing.com South Africa
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP - The Manila Times
What Wall Street predicts for Akari Therapeutics Plc Depositary Receipt stock priceMarket Performance Summary & Weekly Breakout Stock Alerts - newser.com
Akari Therapeutics launches CEO Corner to enhance investor communications By Investing.com - Investing.com India
Form 424B5 Akari Therapeutics Plc - StreetInsider
Akari Therapeutics stock falls after $2.5 million registered offering - Investing.com
Akari Therapeutics secures $2.5 million through registered offering - Investing.com India
$2.5M raise: Akari Therapeutics to issue 3,125,000 ADSs in registered direct offering - Stock Titan
Akari Therapeutics files new patents for cancer treatment technology - Investing.com India
Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 - Sahm
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
Will Akari Therapeutics Plc (Common Stock) (CLA) stock beat revenue estimatesWeekly Profit Analysis & Weekly Market Pulse Alerts - newser.com
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Sahm
A new trading data show Core Scientific Inc (CORZ) is showing positive returns. - Setenews
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Akari’s ADC payload shows promise against resistant prostate cancer By Investing.com - Investing.com South Africa
Akari’s ADC payload shows promise against resistant prostate cancer - Investing.com India
First Potential Treatment for AR-V7 Driven Prostate Cancer: Akari's PH1 Shows Dual Action in Studies - Stock Titan
Can momentum traders help lift Tripadvisor Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com
Analyzing PRA Group Inc. with risk reward ratio chartsJuly 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Akari Therapeutics Plc Adr (AKTX) 財務データ
収益
当期純利益
現金流量
EPS
Akari Therapeutics Plc Adr (AKTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Gaslightwala Abizer | CEO |
Aug 22 '25 |
Buy |
0.93 |
8,000 |
7,440 |
295,574 |
| Gaslightwala Abizer | CEO |
Aug 25 '25 |
Buy |
0.90 |
3,000 |
2,700 |
298,574 |
| Gaslightwala Abizer | President & CEO |
Jun 24 '25 |
Buy |
1.16 |
5,203 |
6,035 |
277,574 |
| Gaslightwala Abizer | President & CEO |
Jun 23 '25 |
Buy |
1.15 |
943 |
1,084 |
272,371 |
| Gaslightwala Abizer | President & CEO |
Jun 20 '25 |
Buy |
1.20 |
10,000 |
12,000 |
271,428 |
| Gaslightwala Abizer | President & CEO |
Jun 17 '25 |
Buy |
1.20 |
15,000 |
18,000 |
261,428 |
0.90%
大文字化:
|
ボリューム (24 時間):